Stockscreener 앱 받기
2.1898
1.40%
0.0398
전일 마감가:
$2.15
열려 있는:
$2.185
하루 거래량:
6,340
Relative Volume:
0.76
시가총액:
$14.52M
수익:
$105.38M
순이익/손실:
$17.78M
주가수익비율:
0.8201
EPS:
2.67
순현금흐름:
$-50.48M
1주 성능:
-2.67%
1개월 성능:
+2.96%
6개월 성능:
-19.26%
1년 성능:
-22.70%
1일 변동 폭
$2.11
$2.198
1주일 범위
$2.10
$2.245
52주 변동 폭
$1.46
$4.10
Mei Pharma Inc Stock (MEIP) Company Profile
명칭
Mei Pharma Inc
전화
858-369-7100
주소
11455 EL CAMINO REAL, SAN DIEGO, CA
MEIP을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MEIP
Mei Pharma Inc
|
2.18 | 14.59M | 105.38M | 17.78M | -50.48M | 2.67 |
|
ONC
Beone Medicines Ltd Adr
|
256.20 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.00 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.232 | 41.83M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.20 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
494.60 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Mei Pharma Inc Stock (MEIP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-07-23 | 다운그레이드 | Laidlaw | Buy → Hold |
| 2022-03-25 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-03-25 | 다운그레이드 | Stifel | Buy → Hold |
| 2022-03-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-02-03 | 개시 | Jefferies | Buy |
| 2020-09-22 | 개시 | Alliance Global Partners | Buy |
| 2020-05-29 | 개시 | SunTrust | Buy |
| 2018-12-20 | 개시 | H.C. Wainwright | Buy |
| 2018-07-27 | 업그레이드 | Stifel | Hold → Buy |
| 2018-07-13 | 개시 | SunTrust | Buy |
| 2016-04-18 | 재확인 | Wedbush | Neutral |
| 2015-03-23 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2014-12-18 | 재확인 | ROTH Capital | Buy |
| 2014-10-16 | 재확인 | ROTH Capital | Buy |
| 2014-07-08 | 재개 | Brean Capital | Buy |
| 2013-10-22 | 재확인 | Stifel | Buy |
| 2013-04-15 | 개시 | Stifel | Buy |
모두보기
Mei Pharma Inc 주식(MEIP)의 최신 뉴스
Northern Trust Corp Increases Stock Holdings in MEI Pharma, Inc. (NASDAQ:MEIP) - Defense World
Marginal Zone Lymphoma Pipeline Appears Robust With 50+ Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
MEI Pharma (NASDAQ:MEIP) Coverage Initiated at StockNews.com - Defense World
1 Beaten-Down Stock to Buy Right Now, and 1 to Avoid - The Globe and Mail
MEI Pharma Reports Significant Revenue Decline - TipRanks
MEIP Explores Strategic Options to Enhance Shareholder Value | M - GuruFocus
MEI Pharma Reports Third Quarter Fiscal Year 2025 Cash Position - GuruFocus
MEI Pharma (NASDAQ:MEIP) Earns Buy Rating from Analysts at StockNews.com - Defense World
This More Than 5%-Yielding Dividend Stock Looks Like a Can't-Miss Buy for Income and Upside Potential - The Globe and Mail
A new MEI study highlights the importance of micro-entrepreneurs in supplying drinking water to poorer neighbourhoods in Ivory Coast - GlobeNewswire Inc.
10 Best NASDAQ Stocks to Buy According to Billionaires - Insider Monkey
Inside Buffett’s $334B Cash Pile: Get Ready for Berkshire Hathaway Earnings - The Globe and Mail
MEI Pharma (NASDAQ:MEIP) Now Covered by StockNews.com - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
StockNews.com Initiates Coverage on MEI Pharma (NASDAQ:MEIP) - Defense World
Follicular Lymphoma Treatment Market 2034: EMA, PDMA, FDA - openPR.com
Follicular Lymphoma Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Prevalence, Revenue, Statistics and Companies by DelveInsight - The Globe and Mail
Sharp Co. (OTCMKTS:SHCAY) Short Interest Down 25.8% in March - The AM Reporter
11 Best Internet Retail Stocks to Buy According to Analysts - Insider Monkey
Billionaire David Tepper’s Top 10 Stock Picks - Insider Monkey
MEI Pharma (NASDAQ:MEIP) Stock Passes Below Two Hundred Day Moving Average – Here’s What Happened - Defense World
MEI Pharma stock hits 52-week low at $1.83 amid market challenges - Investing.com
MEI Pharma stock hits 52-week low at $1.83 amid market challenges By Investing.com - Investing.com South Africa
MEI PHARMA INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus
Follicular Lymphoma Market to Reach New Heights in Growth - openPR.com
Follicular Lymphoma Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Roche, BeiGene, Kite Pharma, Incyte Corp, AstraZeneca, MEI Pharma, Novartis, Innovent Biologics, Regeneron - Barchart.com
Virtu Financial LLC Purchases Shares of 10,744 MEI Pharma, Inc. (NASDAQ:MEIP) - Defense World
MEI Pharma (NASDAQ:MEIP) Now Covered by Analysts at StockNews.com - The AM Reporter
StockNews.com Begins Coverage on MEI Pharma (NASDAQ:MEIP) - Defense World
MEI Pharma stock hits 52-week low at $2.27 amid market challenges - Investing.com Australia
The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors - Business Wire
MEI Pharma (NASDAQ:MEIP) Coverage Initiated by Analysts at StockNews.com - Defense World
MEI Pharma stock hits 52-week low at $2.28 amid market challenges - Investing.com Australia
MEI Pharma stock hits 52-week low at $2.28 amid market challenges By Investing.com - Investing.com South Africa
Will the Stock Market Crash As President Trump's Tariffs Take Effect? History Offers a Clue. - The Globe and Mail
MEI Pharma, Inc. to Host Earnings Call - ACCESS Newswire
10 Cheap Chinese Stocks to Buy Now - Insider Monkey
11 Best Undervalued Stocks to Invest in Now - Insider Monkey
The Polycythemia Vera Market Landscape Heats Up Amid Rising Competition Among Pharma Companies | DelveInsight - The Malaysian Reserve
Cautious Investors Should Wait for THIS Entry Point Before Buying Nvidia Stock - The Globe and Mail
C-COM Antenna Receives Eutelsat Type Approval - The Globe and Mail
Marginal Zone Lymphoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Alarm.com (ALRM) Q4 Earnings: What To Expect - The Globe and Mail
Why Tight Corporate-U.S. Treasury Yield Spreads Signal Good News for Ag Markets Prices - The Globe and Mail
MEI Pharma Reports Increased Losses Amid Strategic Shift - TipRanks
MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position - BioSpace
Mei Pharma Inc (MEIP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.30%
3.35%
자본화:
|
볼륨(24시간):